Forget EpiPens. New treatment for severe allergic reactions skips the needle

ARS Pharmaceuticals is selling the first FDA-approved epinephrine nasal spray to treat allergic reactions.

By Natallie Rocha | natallie.rocha@sduniontribune.com | The San Diego Union-Tribune

UPDATED: October 11, 2024 at 12:03 PM PDT

Richard Lowenthal is the President and Chief Executive Officer of ARS Pharmaceuticals, holds a case for its product Neffy. ARS Pharmaceuticals received FDA approval for Neffy, a nasal spray alternative to the EpiPen. (K.C. Alfred / The San Diego Union-Tribune) — K.C. Alfred / The San Diego Union-Tribune
Richard Lowenthal is the President and Chief Executive Officer of ARS Pharmaceuticals, holds a case for its product Neffy. ARS Pharmaceuticals received FDA approval for Neffy, a nasal spray alternative to the EpiPen. (K.C. Alfred / The San Diego Union-Tribune)

A San Diego company received FDA-approval to sell its epinephrine nasal spray called Neffy.

Subscribe to continue reading this article.

Already subscribed? To log in, click here.

Originally Published: October 11, 2024 at 11:56 AM PDT

Page was generated in 0.05695915222168